This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Aniracetam
Aniracetam is a fat-soluble racetam nootropic known for its combined cognitive-enhancing and anxiolytic effects. It modulates AMPA receptors, enhances creativity and verbal fluency, and reduces anxiety - making it popular for both focus and social situations.
Benefits
What is Aniracetam?
Aniracetam (1-p-anisoyl-2-pyrrolidinone) is a fat-soluble racetam compound developed by Hoffmann-La Roche in the 1970s. It is considered one of the most versatile racetams, offering a unique combination of cognitive enhancement and mood improvement that sets it apart from the more purely cognitive piracetam.
Aniracetam is approximately 5–10 times more potent than piracetam by weight and has a notably different subjective profile. Users consistently report improvements in verbal fluency, creative thinking, holistic (big-picture) processing, and social confidence. It is one of the few nootropics that simultaneously sharpens cognition while reducing anxiety - a combination that makes it particularly popular for social settings, creative work, and public speaking.
Aniracetam has been prescribed in Europe and Japan for age-related cognitive decline and is one of the most well-studied racetams after piracetam, with research spanning over four decades.
- AMPA receptor modulation: Aniracetam is one of the first identified AMPAkines - it positively modulates AMPA glutamate receptors, enhancing synaptic transmission, long-term potentiation (LTP), and memory formation.
- Cholinergic enhancement: Increases acetylcholine release in the prefrontal cortex and hippocampus, supporting memory, attention, and learning.
- Dopaminergic and serotonergic effects: Increases dopamine and serotonin release in the prefrontal cortex, contributing to its anxiolytic and mood-enhancing properties.
- Metabotropic glutamate receptor modulation: Reduces desensitisation of mGluR receptors, further supporting glutamatergic signalling for learning and memory.
- BDNF expression: Some evidence suggests aniracetam upregulates Brain-Derived Neurotrophic Factor, supporting neuroplasticity and long-term brain health.
- Typical dose: 750–1,500 mg per day, divided into 2–3 doses
- Common protocol: 750 mg twice daily
- Half-life: Short (1–2.5 hours) - multiple daily doses are necessary for sustained effects
- Must take with fat: Aniracetam is fat-soluble and must be taken with a meal or fat source (e.g. fish oil, MCT oil) for proper absorption
- With choline: Often stacked with Alpha-GPC or citicoline to prevent headaches and enhance cholinergic effects
- Onset: Effects typically felt within 30–45 minutes
- Side effects: Generally well-tolerated. Possible headache (mitigated by choline supplementation), mild GI discomfort, or insomnia if taken late.
- Toxicity: Very low. Animal studies show extremely high LD50 values. No deaths attributed to aniracetam in humans.
- Drug interactions: Limited data. Use caution with other cholinergic or glutamatergic compounds.
- Pregnancy: Not recommended due to insufficient safety data.
- Legal status: Prescription medication in Europe and Japan (Ampamet, Draganon). Sold as a dietary supplement or research chemical in the US and UK.
Natural Sources & Forms
- Synthetic compound: Does not occur in nature - must be synthesised
- Supplements: Available as capsules and powder from nootropic vendors
- Brand names: Ampamet (Italy), Draganon (Japan), Referan (various)
Frequently Asked Questions
Aniracetam is a fat-soluble racetam nootropic known for its combined cognitive-enhancing and anxiolytic effects. It modulates AMPA receptors, enhances creativity and verbal fluency, and reduces anxiety - making it popular for both focus and social situations.
The key benefits of Aniracetam include: Anxiety & Calm, Cognitive Enhancement, Creativity, Focus, Memory, Mood.
AMPA receptor modulation: Aniracetam is one of the first identified AMPAkines - it positively modulates AMPA glutamate receptors, enhancing synaptic transmission, long-term potentiation (LTP), and memory formation. Cholinergic enhancement: Increases acetylcholine release in the prefrontal cortex and hippocampus, supporting memory, attention, and learning. Dopaminergic and serotonergic effects: Increases dopamine and serotonin release in the prefrontal cortex, contributing to its anxiolytic and mood-enhancing properties. Metabotropic glutamate receptor modulation: Reduces desensitisation of mGluR receptors, further supporting glutamatergic signalling for learning and memory. BDNF expression: Some evidence suggests aniracetam upregulates Brain-Derived Neurotrophic Factor, supporting neuroplasticity and long-term brain health.
Typical dose: 750–1,500 mg per day, divided into 2–3 doses Common protocol: 750 mg twice daily Half-life: Short (1–2.5 hours) - multiple daily doses are necessary for sustained effects Must take with fat: Aniracetam is fat-soluble and must be taken with a meal or fat source (e.g. fish oil, MCT oil) for proper absorption With choline: Often stacked with Alpha-GPC or citicoline to prevent headaches and enhance cholinergic effects Onset: Effects typically felt within 30–45 minutes
Side effects: Generally well-tolerated. Possible headache (mitigated by choline supplementation), mild GI discomfort, or insomnia if taken late. Toxicity: Very low. Animal studies show extremely high LD50 values. No deaths attributed to aniracetam in humans. Drug interactions: Limited data. Use caution with other cholinergic or glutamatergic compounds. Pregnancy: Not recommended due to insufficient safety data. Legal status: Prescription medication in Europe and Japan (Ampamet, Draganon). Sold as a dietary supplement or research chemical in the US and UK.
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!